LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
Journal: 2019/October - National Institute of Diabetes and Digestive and Kidney Diseases
PUBMED: 31643350
Abstract:
Daclizumab is a humanized monoclonal antibody to CD25, the alpha subunit of the IL2 receptor on T lymphocytes, which was used in the past to treat and prevent acute cellular rejection after solid organ transplantation and is currently approved as a second line therapy of refactory relapsing multiple sclerosis. Daclizumab has been linked to occasional mild-to-moderate serum enzyme elevations during therapy, and to rare but potentially severe and fatal instances of immune mediated, clinically apparent liver injury.
Relations:
Diseases
(2)
Drugs
(1)
Genes
(1)
Anatomy
(3)
Similar articles
Articles by the same authors
Discussion board
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.